Reinnervate and Mirus Bio announce collaboration with the launch of the new 3D Transfection System for the transfection of cells cultured in Alvetex®


Sedgefield, UK. November 2011. Reinnervate (Sedgefield, UK) and Mirus Bio (Madison, USA) today announced a commercial agreement to launch a new range of products for the transfection of cells cultured in 3D.

Under the agreement, Mirus will produce and sell kits combining TransIT®-3D Transfection Reagent, Alvetex® 3D cell culture plates and detailed protocols for achieving transfection of selected cell lines growing in 3D.

The kits will enable scientists to evaluate the growth of cells in 3D, allowing more native cell structure, morphology and functionality before transfection with a specific gene of interest with a robust transfection protocol.

“Scientists are increasingly looking for in-vitro cell-based assays that better mimic and predict complex biological processes”, commented Richard Rowling, Commercial Director at Reinnervate. “We believe the 3D Transfection System will be of broad appeal for cell biologists seeking to improve their research capabilities beyond the limitations of mono-layer culture. We are delighted to be collaborating with Mirus to help make 3D cell culture a more routine laboratory technique”.

Scott Hayes (R&D Director of Mirus Bio) added “Cell based research is actively moving towards cellular models, such as 3D cell culture, that more accurately represent intact tissue,”said Scott Hayes, Vice President of Scientific Operations at Mirus Bio, LLC. “With the introduction of the TransIT®-3D Transfection Reagent, Mirus addresses an unmet need for efficient delivery of nucleic acids to cells established and propagated in a 3D cell culture environment. By combining the TransIT®-3D  Transfection Reagent with the innovative scaffold structure of Alvetexplates from Reinnervate, researchers will have access to a cell culture model that is more biologically relevant than routine 2D culture and amenable to easy and high-efficiency transfection.”

Financial terms were not disclosed.